ClinicalTrials.gg
Not yet recruitingNCT06766097Updated Jan 9, 2025

Chios Mastic Toothpaste and Halitosis and Oral Hygiene in Orthodontic Patients

An interventional study of mastic toothpaste and Placebo toothpaste in Halitosis and Orthodontic Appliance Complication, sponsored by University of Athens. Not yet recruiting at 1 site in Greece. Open to participants aged 13 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-09.

Sponsored by University of Athens · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 9 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
13 Years to 18 Years
Sex
All
01

Study summary

The aim of this trial was to investigate the effect of mastic toothpaste on halitosis using as proxy the levels of the Volatile Sulfur Compounds (VSCs), and the effect on plaque and gingival indices in adolescents undergoing orthodontic treatment with fixed conventional labial appliances.

02

Conditions studied

  • Halitosis
  • Orthodontic Appliance Complication

Browse trials for

Keywords

  • Halitosis
  • Mastic
  • Orthodontic appliance
03

In context

Halitosis

93 studies on the registry are indexed under Halitosis; 17 are open to participants now.

This study's planned enrollment of 30 is below the median of 45 across 79 interventional studies indexed under Halitosis.

Browse Halitosis studies →

Lead sponsor

University of Athens is the lead sponsor of 139 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients eligible for the trial must comply with all of the following at randomization:

  • Age between 13 and 18 years for the group with conventional orthodontic appliances.

This age group represents the majority of patients seeking orthodontic treatment and is homogeneous regarding occupational status (high-school and lyceum students in Greece). Younger patients might present with cooperation problems.

  • Good general health.
  • Orthodontic fixed labial appliances on the maxillary and mandibular arch, brackets at least on 20 teeth for more than 4 months before enrollment and estimated duration of the treatment more than 1 month, bands on the first molars, extraction cases patients could be enrolled at least two months after the last extraction.
  • Total initial VSCs levels above the baseline level of 150ppb.

Exclusion criteria

Exclusion Criteria:

Patients will be excluded for any of the following reasons:

  • Active caries
  • Periodontitis
  • Dental fluorosis / dysplasia of the teeth
  • Syndromes, mental disabilities and craniofacial deformities
  • Smoking or use of other tobacco products
  • Allergy to mastic
  • Antibiotics during the last 2 months
  • Chlorhexidine in the previous 3 weeks
  • Participation in other trials
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Experimental group Mastic toothpaste

    Experimental Group: patients, age 13-18, conventional brackets, Mastiha toothpaste 15 patients, with conventional brackets

    Dietary Supplement: mastic toothpaste

  • Placebo comparator
    Placebo control arm: placebo toothpaste

    Control Group: patients, age 13-18, conventional brackets, Placebo toothpaste 15 patients, with conventional brackets

    Dietary Supplement: Placebo toothpaste

Interventions

  • Dietary supplementmastic toothpaste

    All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.

  • Dietary supplementPlacebo toothpaste

    All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.

06

What researchers measure

Primary outcomes

  1. Modified plaque index (PI-M)

    The Silness and Löe index (Silness and Löe, 1964) does not take into account the pattern of plaque accumulation in orthodontic patients. To overcome this problem, Williams et al. (1991) divided the tooth into mesial, distal, gingival, and incisal regions in relation to the bracket and scored plaque in each region using the four codes of the original index (0 to 3). The values are summed to obtain a total score, which ranges from 0 to 12 for each tooth. This modified index is recommended for patients with fixed orthodontic appliances because it acknowledges the usual effects of orthodontic appliances on plaque distribution and has much greater categorical discrimination.

    Time frame: baseline - 2 weeks

  2. Modified plaque index (PI-M)

    The Silness and Löe index (Silness and Löe, 1964) does not take into account the pattern of plaque accumulation in orthodontic patients. To overcome this problem, Williams et al. (1991) divided the tooth into mesial, distal, gingival, and incisal regions in relation to the bracket and scored plaque in each region using the four codes of the original index (0 to 3). The values are summed to obtain a total score, which ranges from 0 to 12 for each tooth. This modified index is recommended for patients with fixed orthodontic appliances because it acknowledges the usual effects of orthodontic appliances on plaque distribution and has much greater categorical discrimination.

    Time frame: 2 weeks

07

Study locations

1 site
  • School of Dentistry
    Athens, Attiki 11527, Greece
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06766097
Responsible party
Iosif Sifakakis (Associate Professor, University of Athens) — Principal investigator
First posted
Jan 9, 2025
Start date
Jan 7, 2025 (estimated)
Primary completion
Jan 31, 2025 (estimated)
Completion
Feb 28, 2025 (estimated)
Last update
Jan 9, 2025

Study contacts

Iosif Sifakakis, Associate Professor
Contact
isifak@dent.uoa.gr
+302107461228
Iosif Sifakakis, Associate Professor
study director · National and Kapodistrian Univrsity of Athens Greece

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion